Swiss biopharma Roche is betting more than $1 billion that Sarepta Therapeutics, which recently won FDA approval for its second RNA medicine for Duchenne muscular dystrophy, will get its lead gene therapy treatment across the finish line too.

The deal, one of the biggest ever US biopharma licensing agreements, gives Roche the right outside of the US to SRP-9001, one of the investigational treatments Sarepta is developing for the fatal genetic disease.

Doug Ingram, president and CEO of Sarepta (NASDAQ: SRPT), said in a Monday conference call that the transaction was the largest single-asset licensing deal in biopharma history for… Read more »